57 results about "Metabolic markers" patented technology

The invention relates to a metabolic marker for diagnosing diabetic secondary osteoporosis and application of the metabolic marker, and belongs to the technical field of biological medicine. The method comprises the following steps: firstly, screening out obviously different metabolites between osteoporosis (DOP) and osteoporosis-free groups (DM) in diabetic patients; and secondly, screening out significant difference metabolites between the primary osteoporosis patient and the healthy control group, and excluding the intersection of the two groups of difference metabolites to obtain metabolites which exclude the influence of the primary osteoporosis. Metabolic markers, namely cytosine nucleotide, ketoglutaric acid and triethylamine, are obtained through further screening, and when the three metabolic markers are independently used, AUCgt; the AUC during combined use is 0.99, so that the limitation that the sensitivity of the traditional bone mineral density detection on the osteoporosis recognition in the diabetic population is insufficient is effectively made up.

The invention discloses a stem cell metabolism marker omics analysis method, device, equipment and medium, relates to the technical field of biomedicine, is applied to a computer device, and comprises the following steps: carrying out non-targeted detection on a to-be-detected sample of a target object to obtain an original mass spectrum; wherein the sample to be detected is a serum sample or a cell sample; preprocessing the original mass spectrogram to obtain a metabolite matrix in a standardized format; performing principal component analysis and partial least square discriminant analysis on the metabolite matrix, and determining a metabolic marker from the metabolite matrix according to an obtained analysis result; obtaining fragment information of the metabolic marker based on a collision-induced dissociation mode, and searching for a structural annotation of the metabolic marker from a human metabolome database based on the fragment information; and constructing a metabolic pathway map of the metabolic marker according to the structural annotation of the metabolic marker. The accuracy of omics analysis of the stem cell metabolism marker is improved.

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The invention belongs to the technical field of medical software development, and particularly relates to a plateau newborn inherited metabolic disease screening system, a computer readable storage medium and application of the plateau newborn inherited metabolic disease screening system. According to the screening system, an altitude hierarchical multi-level reference value database based on a local healthy newborn queue is established, and the problem that the false positive rate of a plain area screening model in a plateau area is too high is solved by fitting an altitude metabolism marker reference median and a standard deviation curve. By designing a'biochemical primary screening-risk scoring-targeted sequencing automatic triggering 'three-level joint control data processing flow, targeted sequencing guided by a crowd specific pathogenic mutation library is started only when the biochemical risk is high, unnecessary whole genome sequencing is avoided, and the screening cost is remarkably reduced. The system can continuously iterate a reference curve and a risk threshold value according to definite diagnosis data, and closed-loop dynamic optimization from sample collection to report generation is achieved. The method has plateau adaptability, crowd specificity and cost controllability, and has a good clinical application prospect.

The invention provides application of acetylcholine and 1-carboxyl-6-hydroxy-3, 4-dihydro-beta-carboline (the code in the attached drawing of the abstract is CHEMBL461889) in early pregnancy diagnosis, non-targeted metabonomics detection and analysis are carried out on the urine of pregnant and non-pregnant sows by virtue of a liquid chromatography-mass spectrometry technology; the two metabolic markers capable of being used for early pregnancy diagnosis of the sows are screened out by introducing two deep learning models for joint analysis, the AUC values of ROC curves of the two metabolic markers are 1, the accuracy is very high, and the pregnancy state of the sows can be accurately judged only 18 days after the sows are bred. The invention provides a novel effective sow early pregnancy diagnosis method for the pig breeding industry, and has important significance for reducing the breeding cost.

The invention discloses application of a metabonomics marker combination in preparation of a product for identifying benign and malignant lung ground glass nodules. The metabonomics marker combination comprises the following 11 metabonomics markers: 5 '-S-methyl-5'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'- And gamma-glutamylglutamic acid; the component A is N-stearoyl-D-red sphingosine; sphingosine; palmitoyl ethanolamide; 2-(4-(diethylamino) butyl-2-alkyne-1-yl) isoindene-1, 3-diketone is used as a raw material; vesenadine; zolpidem; the preparation method comprises the following steps: adding 4-hydroxyl-3-(2 '-hydroxyl-1, 1'-biphenyl-4-yl)-6-oxo-6, 7-dihydrothieno [2, 3-b] pyridine-5-formonitrile into a reaction kettle, and stirring for 20-30 minutes; and D-erythro-sphingosine; the invention relates to 3-methylpyrrole-2, 4-dicarboxylic acid. According to the invention, 11 specific metabolic markers closely related to benign and malignant lung ground glass nodules are found, the AUC value of a diagnosis model constructed on the basis of the 11 metabolic markers is up to 0.888, and the diagnosis model has extremely high identification accuracy and specificity.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

The invention discloses application of a metabolic marker in preparation of an eye myasthenia gravis diagnostic reagent, and belongs to the technical field of biological medicine. According to the constructed OMG evaluation model, the AUROC for distinguishing an OMG patient from a healthy sample is 0.920 (95% CI: 0.874-0.965), which shows that the overall discrimination ability is high; according to the present invention, the detection results show that the average precision is 0.956 (95% CI: 0.922-0.990), the sensitivity is 0.816 (95% CI: 0.736-0.901), the specificity is 0.940 (95% CI: 0.870-1.000), and the precision is 0.959 (95% CI: 0.909-1.000); the model is excellent in overall distinguishing ability and prediction accuracy, and OMG patients can be effectively identified.

The application discloses a lung nodule metabolic marker and a screening method and a construction method and application of a screening model. Specifically disclosed are the application of metabolic markers and / or reagents for detecting the metabolic markers in the preparation of products for lung nodule screening; the metabolic markers include hypoxanthine, L-ornithine, decanoyl-L-carnitine, dehydroepiandrosterone sulfate and bethanidine. The application further discloses a method for constructing a lung nodule screening model. The metabolic markers and the lung nodule screening model constructed by using the metabolic markers can effectively screen out individuals with lung nodules from healthy people, have very high sensitivity and good specificity, are fast, accurate, non-invasive and non-radiation, are suitable for wide promotion, can be used as a pre-screening tool of LDCT, are used for the preliminary screening of lung nodules of a large-scale population, and have important significance for the early discovery of lung cancer and the improvement of the prognosis of patients.

The invention provides a metabolic marker combination for identifying okra related species, an identification method and application of the metabolic marker combination, and belongs to the technical field of drug detection. The identification method provided by the invention comprises the following steps: carrying out non-targeted metabonomics detection on dry powder samples of Abelmoschus manihot (L.) Medik., Abelmoschus moschus (L.) Meduli, Abelmoschus sagittifolius (L.) Merr. And Abelmoschus esculentus (L.) Moench by adopting ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS), so as to obtain metabolite data, and carrying out quantitative analysis on the metabolite data, so as to obtain a sample of the Abelmoschus manihot (L.) Meduli, the sample of the Abelmoschus moschus (L.) Merr. And carrying out mass spectrum qualitative and quantitative analysis on metabolite data, and screening out common differential metabolites among the four plants as characteristic metabolites to realize variety identification of okra related species. The method can effectively distinguish okra species with similar morphologies, and has application value in traditional Chinese medicinal material original identification, germplasm resource screening and variety purity detection in a seedling raising stage.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

A method for evaluating the effect of a drug on a tumor and tumor-related cells. The tumor and the tumor-related cells are cultured in a culture medium containing a to-be-tested drug and a metabolic marker containing deuterium, the tumor and the tumor-related cells are imaged by means of coherent Raman scattering microscopy, and a metabolic product signal of the metabolic marker in an image is quantified, so as to evaluate the effect of the to-be-tested drug on the tumor and the tumor-related cells. According to the provided method, by means of quantifying unique chemical bonds that are newly generated after cellular metabolism, different cell samples can be subjected to drug effect detection based on the differences in metabolic inhibition by means of the same detection scheme. The method is simple and rapid, requiring a short culture time, which avoids the influence of prolonged culture on various properties of cells. The method has a better universality while reducing the detection cost.

The invention discloses application of a reagent for detecting a plasma metabolism marker combination in preparation of a product for diagnosing breast cancer, and belongs to the field of breast cancer markers. According to the application of the reagent for detecting the plasma metabolism marker combination in preparing the product for diagnosing the breast cancer, the plasma metabolism marker combination comprises dehydroepiandrosterone sulfate, acylcarnitine 12: 0 and taurodeoxycholic acid. The plasma metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for breast cancer detection, so that a subject can conveniently and safely receive detection, and the plasma metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of breast cancer.

The application discloses a novel metabolic marker for preparing a medicine for treating liver cancer and application thereof. By constructing an ALDH6A1 overexpression liver cancer cell line, it is found through detection that the level of methylcitrate in the cell is inversely proportional to the proliferation and migration rate of liver cancer cells. In Aldh6a1 knockout mice, an AKT / NRAS liver cancer model is constructed by high-pressure tail vein injection, and it is found that the content of methylcitrate in the serum is inversely proportional to the levels of ALT and AST in the serum of the mice and inversely proportional to the liver cancer load of the mice. The metabolite methylcitrate can not only effectively inhibit the proliferation of liver cancer cells alone, but also can enhance the inhibitory effect of sorafenib on the proliferation of liver cancer cells. The metabolite can effectively inhibit the formation of tumors, can be used as a metabolic marker for detecting liver cancer, and can more accurately and efficiently judge the severity of liver cancer; and can be used as a novel metabolite for treating liver cancer, and can improve the treatment effect of liver cancer.

The invention provides a multi-omics integrated marker for early screening of colorectal cancer, which comprises an lncRNA marker combination, a protein marker combination, an mRNA marker combination, a metabolism marker combination and a methylation marker combination, and relates to the technical field of gene detection and medical treatment. According to the invention, 11 groups of colorectal cancer tissues and para-carcinoma tissues paired with the colorectal cancer tissues are subjected to transcriptome, proteome and metabolome sequencing, and 61 cases of colorectal cancer tissues and 24 cases of para-carcinoma tissues are subjected to simplified methylation sequencing; by integrating and analyzing the multi-omics data, a multi-level interaction network is obtained, and the network contains lncRNA, protein, mRNA, metabolites and DNA methylation markers which have a close interaction relationship, and has a wide application prospect in diagnosis and treatment of colorectal cancer.

The application discloses a metabolic marker for distinguishing metabolic syndrome and simple obesity and application thereof. The marker comprises eight metabolites, i.e. glycocholic acid, lithocholic acid, linoleic acid, valine, leucine, alanine, serine and glycine. The application performs non-targeted metabolomics analysis on serum of metabolic syndrome and simple obesity patients by liquid chromatography mass spectrometry, finds eight metabolites with significant difference between the two, and finds that the eight metabolic markers have high AUC when used for diagnosing and distinguishing metabolic syndrome patients or simple obesity patients alone or in combination.

To provide a method for determining odor of fish, especially odor deterioration and lipid oxidation degree of tilapia during cold storage.SOLUTION: The method includes the steps of: killing fresh tilapia, slicing, washing, mixing and grinding the fish meat to obtain raw materials; extracting lipids from the raw materials; dividing the obtained lipids and storing them under low-temperature conditions, and after storage, measuring the lipid oxidation degree and lipid metabolic data of tilapia at different refrigeration times using lipid metabolomics technology; constructing an odor-related lipid metabolic network and analyzing the lipid oxidation degree and metabolic data at different refrigeration times based on the lipid metabolic network to obtain metabolic markers corresponding to multiple lipids; screening the obtained metabolic markers to obtain evaluation metabolic markers; and analyzing the oxidation degree and metabolic status of multiple lipids based on the evaluation metabolic markers corresponding to multiple lipids.SELECTED DRAWING: Figure 1

This invention provides a set of metabolic biomarkers for assessing perfluorooctane sulfonate (PFOS) exposure levels and their applications, belonging to the field of organic pollutant poisoning detection technology. Utilizing plasma sample metabolomics data and machine learning algorithms, this invention successfully constructs a discriminant model capable of accurately distinguishing between high PFOS exposure (above 20 ng / mL) and low exposure (not exceeding 20 ng / mL). This method is simple to operate, non-invasive, and the sample collection process is quick and easy, making it particularly suitable for large-scale PFOS high exposure risk screening in populations. It eliminates the need for PFOS standards, avoiding potential contamination risks.

Provided are methods and systems for detecting a polymorphism in one or more glucagon-like protein-1 receptor (GLP-1R) related markers, and optionally detecting one or more metabolic markers or neural markers, in a subject. Also provided are methods and systems for predicting a risk for developing GLP-1R associated condition or a response to a GLP-1R agonist therapy in a subject by detecting a polymorphism in one or more GLP-1R related markers, and optionally detecting one or more metabolic markers or neural markers. The methods and systems can be used for selecting a treatment regimen, monitoring a response to the treatment, or adjusting the treatment regimen in the subject.

The invention discloses application of a Homer 1 gene in regulating and controlling the water-holding capacity character of a pig, and belongs to the technical field of biology. Candidate genes related to the water-holding capacity are analyzed and screened through transcriptomics; and identifying proteins and metabolic markers related to the water-holding capacity in the longissimus dorsi aging process by utilizing metabonomics and proteomics technologies. And carrying out cellular level function verification on the screened key gene Homer 1 through multi-omics integration analysis. The result shows that the Homer 1 gene is negatively correlated with the water-holding capacity, so that a theoretical basis is provided for understanding a regulation mechanism of the water-holding capacity of the pig skeletal muscle; meanwhile, candidate gene resources and theoretical support are provided for breeding of high-quality and high-efficiency new pig varieties.

The invention relates to the technical field of metabolic markers, in particular to application of metabolic markers in preparation of products for detecting or diagnosing coronary heart disease adverse cardiovascular events and a construction method of a coronary heart disease adverse cardiovascular event diagnosis model. The coronary heart disease adverse cardiovascular event product is used for detecting or diagnosing coronary heart disease cardiovascular death events and / or coronary heart disease heart failure events. According to the application, the risks of death events and heart failure events of the coronary heart disease patients are predicted by using the specific differential metabolites, dense monitoring can be performed on the coronary heart disease patients, and effective customized treatment guidance is provided for clinicians.

The invention provides application of quercetin in preparation of a medicine for regulating intestinal microbiological disorder caused by bladder cancer, and belongs to the technical field of medical technology. It is found for the first time that quercetin regulates intestinal flora in the occurrence and development process of bladder cancer, effectively enriches tumor-related intestinal beneficial bacteria, can reverse disorder of in-vivo metabolic markers and reduces the level of L-serine, and therefore the effect of inhibiting the progress of bladder tumor is achieved.

The invention provides a metabolic marker combination for diagnosis or auxiliary diagnosis of kidney cancer and application of the metabolic marker combination, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for diagnosis or auxiliary diagnosis of kidney cancer. The metabolic marker combination comprises L-glucan and aspartic acid, the metabolism marker comprises a blood metabolism marker or a urine metabolism marker. The diagnosis model for distinguishing healthy individuals and kidney cancer patients is constructed by adopting L-glucan and aspartic acid, so that the diagnosis efficiency is high, and the clinical diagnosis significance is realized. In addition, 12 metabolic markers, 10 metabolic markers, 8 metabolic markers, 6 metabolic markers and 4 metabolic markers containing L-glucan and aspartic acid are respectively subjected to construction of diagnosis models for distinguishing healthy individuals from kidney cancer patients, and the constructed diagnosis models have relatively high diagnosis efficiency; the clinical diagnosis significance is realized.

Use of metabolic markers for diagnosing stages of lung cancer and a kit are provided. Use of metabolic markers for diagnosing stages of lung cancer and one or more of a detection reagent for the metabolic markers for diagnosing stages of lung cancer in preparation of a kit for diagnosing the stages of lung cancer are provided. A kit for diagnosing stages of lung cancer is provided, including metabolic markers for diagnosing stages of lung cancer and one or more of a detection reagent for the metabolic markers for diagnosing stages of lung cancer.

The invention relates to a dielectric wetting valve micro-fluidic chip for metabolic marker detection and a preparation method of the dielectric wetting valve micro-fluidic chip. A chip middle layer is stacked above a chip lower layer, and an inverted chip upper layer is stacked above the chip middle layer; the chip middle layer comprises a double-sided adhesive layer and a trident micro-channel, the periphery of the trident micro-channel is coated with the double-sided adhesive layer, the trident micro-channel comprises a central area, a first branch channel, a second branch channel and a third branch channel, and the first branch channel, the second branch channel and the third branch channel are uniformly distributed on the periphery of the central area; the head end of the first branch channel, the head end of the second branch channel and the head end of the third branch channel are respectively connected with the central area. Through the trident micro-channel, the detection of various metabolic markers becomes simpler, more convenient and more sensitive, and the detection precision of the metabolic markers is improved. According to the invention, through the trifurcate micro-channel, the sequential analysis of various targeted metabolites can be realized, an external pump is not needed, and the device has the advantages of high portability, accurate fluid control and the like.

The invention relates to a group of metabolic markers and application thereof in preparation of products for screening and / or diagnosing depression. The metabolic marker is prepared from one or more of 4-oxo-2-propyl valeric acid, diethylstilbestrol, cyclo (leucine-valine) peptide, 6-benzylaminopurine and 3-carboxyl-4-methyl-5-pentyl-2-furanpropionic acid, and the metabolic marker is prepared from one or more of the following components: 4-oxo-2-propyl valeric acid, diethylstilbestrol, cyclo (leucine-valine) peptide, 6-benzylaminopurine and 3-carboxyl-4 According to the application, research finds that 4-oxo-2-propyl valeric acid, diethylstilbestrol, cyclo (leucine-valine) peptide, 6-benzylaminopurine and 3-carboxyl-4-methyl-5-pentyl-2-furanpropionic acid can be used as metabolic markers, and high-sensitivity and high-specificity screening diagnosis is carried out on the depression.

The invention discloses a biological system based on metabolic affinity and application of the biological system in preparation of antitumor drugs and detection kits. According to the system, selective metabolic affinity screening is carried out based on living microorganisms through an in-vitro adaptability protocol, and selective recognition of a tumor microenvironment, local generation of a bioactive agent and biological restraint are achieved. The system integrates chemotropism detection of tumor metabolic markers, biologic and adaptive decision based on nutritional gradients, controlled production of biologically active metabolites, and a safety architecture. And the self-amplification treatment effect in proportion to the tumor load is realized through a nutrition chemical trend mechanism. The invention aims to eliminate systemic toxicity of traditional chemotherapy through concentration gradient mediated super localized release, reduce production cost through controlled self-replication in continuous flow biological reaction, and guarantee safety through immune clearance. Affinity can be obtained through a metabolic adaptation experiment, the method is suitable for various tumors through a modular reselection protocol, and a new direction is provided for metastatic cancer treatment.

The invention discloses a metabolic marker for diagnosing lung function grading in a stable phase of chronic obstructive pulmonary disease and application of the metabolic marker. According to the invention, in a training set, the lysophosphatidylcholine (17: 0 / 0: 0) is combined with the dimethylglycine or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the 5-hydroxyindoleacetic acid or the lysophosphatidylcholine (17: 0 / 0: 0), and the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0). The combination of the L-pyroglutamic acid and the 5-hydroxyindoleacetic acid has excellent diagnosis efficiency in diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the chronic obstructive pulmonary disease in the stable phase; further, verification results in a verification set show that the four combined metabolic markers have excellent accuracy in combined diagnosis and distinguishing of patients with the lung functions of the chronic obstructive pulmonary disease at the 1-2 level and the 3-4 level in the stable phase. Therefore, the four combined metabolic markers have the prospect of being developed into a kit for diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the stable-phase chronic obstructive pulmonary disease.